Literature DB >> 10564525

Widespread occurrence of alpha-synuclein/NACP-immunoreactive neuronal inclusions in juvenile and adult-onset Hallervorden-Spatz disease with Lewy bodies.

K Wakabayashi1, M Yoshimoto, T Fukushima, R Koide, Y Horikawa, T Morita, H Takahashi.   

Abstract

Alpha-Synuclein (originally called precursor of the non-Abeta component of Alzheimer's disease amyloid-NACP) is a presynaptic nerve terminal protein and is now known to be a major component of Lewy bodies (LBs) in Parkinson's disease. Previous studies have shown that LBs are occasionally found in patients with Hallervorden-Spatz disease (HSD), a hereditary or sporadic neuroaxonal dystrophy. Therefore, an immunocytochemical examination of the brain tissues from two patients with HSD for alpha-synuclein/NACP was performed. In both cases, LBs were observed in the substantia nigra, locus ceruleus and other subcortical nuclei. These LBs were strongly immunolabelled with anti-alpha-synuclein/NACP. Moreover, abnormal alpha-synuclein/NACP-immunoreactive structures in the neuronal somata and processes were found in the cerebral neocortex, hippocampus, basal ganglia, thalamus, pontine and inferior olivary nuclei, spinal grey matter, and peripheral sympathetic ganglia. Although numerous dystrophic axons (spheroids) were found throughout the brain, either none or only a few were positive for alpha-synuclein/NACP. These findings suggest that widespread accumulation of alpha-synuclein/NACP is a pathological feature in patients suffering from HSD with LBs, and that this phenomenon is unrelated to axonal spheroid formation.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10564525     DOI: 10.1046/j.1365-2990.1999.00193.x

Source DB:  PubMed          Journal:  Neuropathol Appl Neurobiol        ISSN: 0305-1846            Impact factor:   8.090


  18 in total

1.  Selective insolubility of alpha-synuclein in human Lewy body diseases is recapitulated in a transgenic mouse model.

Authors:  P J Kahle; M Neumann; L Ozmen; V Müller; S Odoy; N Okamoto; H Jacobsen; T Iwatsubo; J Q Trojanowski; H Takahashi; K Wakabayashi; N Bogdanovic; P Riederer; H A Kretzschmar; C Haass
Journal:  Am J Pathol       Date:  2001-12       Impact factor: 4.307

2.  Neurodegeneration with brain iron accumulation, type 1 is characterized by alpha-, beta-, and gamma-synuclein neuropathology.

Authors:  J E Galvin; B Giasson; H I Hurtig; V M Lee; J Q Trojanowski
Journal:  Am J Pathol       Date:  2000-08       Impact factor: 4.307

Review 3.  The Lewy body in Parkinson's disease and related neurodegenerative disorders.

Authors:  Koichi Wakabayashi; Kunikazu Tanji; Saori Odagiri; Yasuo Miki; Fumiaki Mori; Hitoshi Takahashi
Journal:  Mol Neurobiol       Date:  2012-05-24       Impact factor: 5.590

Review 4.  Neurodegeneration with brain iron accumulation.

Authors:  Allison Gregory; Susan J Hayflick
Journal:  Folia Neuropathol       Date:  2005       Impact factor: 2.038

5.  Altered neuronal mitochondrial coenzyme A synthesis in neurodegeneration with brain iron accumulation caused by abnormal processing, stability, and catalytic activity of mutant pantothenate kinase 2.

Authors:  Paul T Kotzbauer; Adam C Truax; John Q Trojanowski; Virginia M-Y Lee
Journal:  J Neurosci       Date:  2005-01-19       Impact factor: 6.167

Review 6.  Molecular mechanisms of alpha-synuclein neurodegeneration.

Authors:  Elisa A Waxman; Benoit I Giasson
Journal:  Biochim Biophys Acta       Date:  2008-10-09

7.  Disrupted membrane homeostasis and accumulation of ubiquitinated proteins in a mouse model of infantile neuroaxonal dystrophy caused by PLA2G6 mutations.

Authors:  Ibrahim Malik; John Turk; David J Mancuso; Laura Montier; Mary Wohltmann; David F Wozniak; Robert E Schmidt; Richard W Gross; Paul T Kotzbauer
Journal:  Am J Pathol       Date:  2008-01-17       Impact factor: 4.307

Review 8.  Clinical and genetic delineation of neurodegeneration with brain iron accumulation.

Authors:  A Gregory; B J Polster; S J Hayflick
Journal:  J Med Genet       Date:  2008-11-03       Impact factor: 6.318

Review 9.  Biophysics of Parkinson's disease: structure and aggregation of alpha-synuclein.

Authors:  Vladimir N Uversky; David Eliezer
Journal:  Curr Protein Pept Sci       Date:  2009-10       Impact factor: 3.272

10.  Proteome response to the panneural expression of human wild-type alpha-synuclein: a Drosophila model of Parkinson's disease.

Authors:  Zhiyin Xun; Thomas C Kaufman; David E Clemmer
Journal:  J Proteome Res       Date:  2008-08-07       Impact factor: 4.466

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.